AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06087952 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Advise to continue anticoagulant treatment after 3 months
Description: Advise to continue anticoagulant treatment after 3 months for patients with high VTE recurrence and low bleeding risk
Study NCT06087952 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Advise to discontinue anticoagulant treatment after 3 months
Description: Advise to discontinue anticoagulant treatment after 3 months for patients with low VTE recurrence risk
Study NCT05713071 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric Endoscopic Antral Myotomy
Description: BEAM will be performed using a standard gastric peroral endoscopic myotomy (G-POEM) technique, however with the myotomy targeting only the antrum and leaving the pyloric ring intact. G-POEM is commonly and widely employed for gastric emptying and nutritional issues and is covered by most insurance plans. This involves injecting fluid into the submucosal space, making a mucosal incision to enter the submucosal space, and tunneling along the antrum to the pylorus. A myotomy is then performed, however, in BEAM the pyloric ring is spared and the myotomy is only performed in the antrum. The incision is then closed with clips. No endoscopic suturing will be performed.
Study NCT04796038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon dilatation
Description: Patient will be treated with balloon dilatation either stand-alone (POBA) or followed by stent implantation.
Study NCT05111288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy (PEMF)
Description: Pulsed electromagnetic field (PEMF) therapy is a noninvasive technique, which provides low field electromagnetic stimulation. The therapy of PEMF is achieved by altering biological and physiological systems via low energy and non-ionizing electromagnetic fields.
Study NCT05111288 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive Pulsed electromagnetic field therapy (PEMF)
Description: PEMF device that turns on but does not provide any electromagnetic stimulation
Study NCT05366712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stryker Trident® II HA coated cementless acetabula component
Description: New acetabula component.
Study NCT04445662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Escalating financial rewards for saliva cotinine levels \<30 ng/mL, assessed 10 times over 12 weeks
Study NCT04445662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: * Day 1 - 3: 0.5 mg daily~* Day 4 - 7: 0.5 mg twice daily~* Day 8 - Week 12: 1 mg twice daily~* Dose/schedule may be adjusted based on medical history and clinician judgement
Study NCT04445662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: * Day 1 - 3: 0.5 mg daily~* Day 4 - 7: 0.5 mg twice daily~* Day 8 - Week 12: 1 mg twice daily~* Dose/schedule may be adjusted based on medical history and clinician judgement
Study NCT04445662 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco coaching
Description: 5 one-on-one tobacco cessation coaching sessions over 12 weeks
Study NCT04445662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco coaching
Description: 5 one-on-one tobacco cessation coaching sessions over 12 weeks
Study NCT06530277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REMINDer (A digital environmental enrichment intervention)
Description: REMINDer adapts the REMIND program (Nicotra et al., 2022) for telehealth, integrating cognitive, motor, sensory, emotional, and social stimulation through music, dance-based movement, and mindfulness. The program consists of 2 online sessions/week for 60 minutes each over 6 weeks, led by trained facilitators experienced in dance movement therapy and mindfulness exercises. Sessions are divided into welcome/warm-up (10 min), training (40 min), and relaxation/feedback (10 min) phases. Using a structured manual, participants perform exercises that address the program's multimodal stimulation. The REMINDer program is delivered in a group setting via an online videoconferencing system. The intervention, no intervention (AB) group undergoes the training program between t1 and t2 and then resumes their normal lifestyle from t2 to t3. The no intervention, intervention group (BA) maintains its normal lifestyle from t1 to t2 and then participates in the training program from t2 to t3.
Study NCT06482086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 8/10/12 mg qd, po. Stop the medication for one week after taking it for two weeks.
Study NCT04850521 — intervention group
Intervention type: OTHER
Intervention: Remote monitoring
Description: patient-facing app + connected spirometer + connected pulse oximeter + clinician view portal
Study NCT05909150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chloride solution 3,5%
Description: Patients will receive 150 mL HSS 3,5% intravenous twice daily for 3 days after heart transplantation.
Study NCT05909150 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride solution 0,9%
Description: Patients will receive 150 mL NS 0,9% intravenous twice daily for 3 days after heart transplantation.
Study NCT04846296 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: The QLPSD, developed in Spain, was the first questionnaire designed to evaluate HRQoL in adolescents with spinal deformities. It has shown good validity and reliability. English, French and Persian versions of the QLPSD have been developed and validated. Good reliability and ease of use are mentioned in these versions. The QLPSD was designed to examine adolescents with spinal deformities and measure the effect of orthotic and surgical treatments on QoL.
Study NCT06482086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 8/12 mg qd, po.
Study NCT06482086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 0.4 g bid, po.
Study NCT06482086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: 0.3 g bid, po.
Study NCT06482086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg qd, po.
Study NCT06482086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500 mg qd, po.
Study NCT06482086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib + Trametinib
Description: Dabrafenib 150 mg bid, po+Trametinib 2 mg qd, po.
Study NCT06482086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib 60mg qd, po.
Study NCT06482086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Vandetanib 300mg qd, po.
Study NCT06482086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Entrectinib 600mg qd，po.
Study NCT06556407 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: renal denervation
Description: ultrasound based renal denervation
Study NCT06482086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralsetinib
Description: 400mg qd, po.
Study NCT06482086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib
Description: 100mg qd，po
Study NCT04881682 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immunoadsorption
Description: see arm/group description
Study NCT04881682 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Immunoglobulins
Description: see arm/group description
Study NCT06567002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6552
Description: Oral Administration
Study NCT04106115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg IV infusion every 4 weeks for up to 7 doses
Study NCT04106115 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S-488210/S-488211
Description: S-488210/S-488211 is given as a 1 mL subcutaneous (SC) injection of S-488210/Montanide emulsion and a 1 mL SC injection of S-488211/Montanide emulsion starting the day after first dose of durvalumab and continuing weekly for 6 doses and then every 2 weeks for a further 9 doses
Study NCT05325203 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ongericimab
Description: Administered by subcutaneous injection
Study NCT05325203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study NCT06475586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: 0.25mg 4 weeks, 0.5mg per 4 weeks and 1.0mg per 4 weeks, totally 12 weeks
Study NCT05036759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI
Description: intravenously injected with 68Ga-FAPI
Study NCT05043129 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biological/Vaccine: SARS-COV-2 VACCINE
Description: The antibody titer and adverse reactions were observed.
Study NCT06504706 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Matcha Tea
Description: Japanese tea rich in antioxidants and Catechins
Study NCT06504706 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Green Tea
Description: Green tea rich in catechins
Study NCT06024460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-pharmacological treatment strategy
Description: Acupuncture, elctroacupuncture, spinal manual therapy, motion style acupucnture treatment
Study NCT06024460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological treatment strategy
Description: Prescription medication, injection therapy, nerve blocks, or other pharmacological interventions commonly used for managing lumbar disc herniation.~This group is treated using the above treatment strategies, and no drug is specified.
Study NCT06312046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HiBalance-MS
Description: See arm description for intervention group.
Study NCT06461312 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined pulsed radiofrequency of the pudendal nerve with ganglion impar block
Description: Combined pulsed radiofrequency of the pudendal nerve with ganglion impar block
Study NCT05497895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5% thymoquinone (TQ) gel
Description: Mode of Administration In Group I patients, the lipid based TQ gel (5%) will be applied topically to the affected areas, twice daily for two weeks following SRP. The investigator performing the treatment of gingivitis based on the patient's response to therapy. For home care, the patients will be instructed to clean and dry the affected area prior to the gel application and hands will be washed prior and after its application. The patients will be instructed to not eat for 30 minutes following its application.
Study NCT05497895 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SRP and placebo
Description: In Group II patients, the placebo gel will be applied topically to the affected areas, twice daily for two weeks following SRP. The investigator performs the treatment of gingivitis based on the patient's response to therapy. For home care, the patients will be instructed to clean and dry the affected area prior to the gel application and hands will be washed prior to and after its application. The patients will be instructed to not eat for 30 minutes following its application
Study NCT04650295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Household Remedy
Description: If the participant experiences a muscle cramp one tablespoon (one sip) of the household product will be taken. The treatment phase of the study will be for 28 days.
Study NCT04650295 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tap water
Description: If the participant experiences a muscle cramp one tablespoon (one sip) of tap water will be taken. The treatment phase of the study will be for 28 days.
Study NCT06495892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuretic therapy
Description: Diuretic therapy will be tailored according to peripheral venous pressure targets or standard approach
Study NCT06495892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diuretic therapy
Description: Diuretic therapy will be tailored according to peripheral venous pressure targets or standard approach
Study NCT05920174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEO
Description: Subjects will be implanted with the NEO device.
Study NCT05497895 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Only SRP-one stage prophylaxis
Description: The Group III patients will be subjected to one-stage oral prophylaxis.
Study NCT04792190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapagliflozin
Description: Subjects will take 1 blinded tablet of study drug (dapagliflozin 10 mg) dosed once daily, for 12 months.
Study NCT04792190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take 1 blinded capsule of placebo drug dosed once daily
Study NCT05653700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arena Strive
Description: This second-generation platform provides frontline clinicians with a comprehensive journey to access the tools, training, and technology used by other high-pressure fields to increase performance and enhance resilience. The experimental intervention employed in this study will be a 12-week, multi-phased approach involving an asynchronous learning and coaching experience (6 weeks), and exploration phase (6 weeks).
Study NCT05653700 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Cohort
Description: Participants randomized into the control cohort - survey at baseline and end of the study
Study NCT04945824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Ophthalmic
Description: Insertion Device: A handheld mechanical device used by the clinician to dilate the punctum and deliver the DEXTENZA insert into the canaliculus; designed to be single-use and pre-loaded with a single DEXTENZA insert.
Study NCT04945824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dilator
Description: Intracanalicular Dilator Device
Study NCT05480254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clamped catheter
Description: Q3 clamped catheter protocol is applied before urinary catheter removal
Study NCT06394284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA-AT
Description: As described above in arm description
Study NCT06394284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEA-IT
Description: As described in arm description
Study NCT05704439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neurologist Initiated Treatment
Description: Neurologist Initiated Treatment for Hypertension or Hyperlipidemia
Study NCT05704439 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Usual care
Study NCT06322706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABSK021
Description: ABSK021 oral
Study NCT06322706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole oral
Study NCT05216068 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: NGS
Description: Based on the next generation sequencing (NGS), WES can identify single nucleotide variants (SNVs) and small variants.
Study NCT05690334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crystalloid - 0 ml/kg
Description: No fluid coload was given. An initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Study NCT05690334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crystalloid - 5 ml/kg
Description: 5 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Study NCT05690334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crystalloid - 10 ml/kg
Description: 10 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Study NCT05875376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple group therapy
Description: 1. Introduction of I statements~2. Focus of each conversation~3. Emotion acknowledgement~4. Self-assurance and positive feedback~5. teamwork and cooperation~6. Reflection
Study NCT05918224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Streptococcus salivarius K12
Description: The patients in intervention group were treated with Streptococcus salivarius K12 lozenges three times a day after gargling from the first day of radiotherapy up to 1 week after the end of treatment. Streptococcus salivarius K12 is dissolved in the mouth and then swallowed.
Study NCT05530278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galicaftor
Description: Oral
Study NCT05530278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-576
Description: Oral
Study NCT05918224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Streptococcus salivarius K12 simulants
Description: Patients in control group were treated with Streptococcus salivarius K12 simulants, and its use method and use time are the same as intervention group.
Study NCT05371431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional rehabilitation training
Description: The non-BFR group undertook traditional rehabilitation training only. Patients participated in 2 training sessions per week with at least 48 hours rest in between for continuous 6 weeks. Clinical assessment of grip strength, pinch strength (tip pinch strength, key pinch strength and tripod pinch strength), ROM of wrist, PRWE score, muscle stiffness and radiographic outcomes, was conducted at the 6th and 12th week from the date of initial DRF.
Study NCT05371431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction combined with traditional rehabilitation training
Description: BFR group completed the traditional rehabilitation training with a medical grade tourniquet applied on the upper arm. Patients participated in 2 training sessions per week with at least 48 hours rest in between for continuous 6 weeks. Clinical assessment of grip strength, pinch strength (tip pinch strength, key pinch strength and tripod pinch strength), ROM of wrist, PRWE score, muscle stiffness and radiographic outcomes, was conducted at the 6th and 12th week from the date of initial DRF.
Study NCT05847439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]BMS-986419
Description: Specified dose on specified days
Study NCT05355714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sofwave
Description: High-Frequency Non-Focused Ultrasound Device
Study NCT05355714 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultherapy
Description: Microfocused Ultrasound with Visualization
Study NCT05530278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navocaftor
Description: Oral
Study NCT05530278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral
Study NCT05157399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Otoband
Description: Participants with Dizziness and Vertigo will wear the Otoband set at normal power (effective) during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
Study NCT05157399 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Device
Description: Participants with Dizziness and Vertigo will wear the placebo device set at low power during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
Study NCT06488924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-446
Description: IV infusion
Study NCT06160323 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided coeliac ganglion neurolysis / celiac plexus neurolysis
Description: The EUS scope was first inserted into the stomach, and the coeliac trunk was visualized by scanning from the lesser curve of the gastric body. After visualization, the scope was rotated clockwise, enabling visualization and identification of the left adrenal gland. The coeliac ganglia are often seen to the left of the coeliac artery, between the aorta and the left adrenal gland, at the level between the coeliac artery and the left adrenal artery. They are also visualized cephalad to the coeliac artery in some cases. Hypoechoic nodular structures linked by hypoechoic threads residing in the periphery of this region were defined as the coeliac ganglia . A 19G or 22G needle was used for puncture of the CGN. After confirming the lack of backflow of blood with aspiration, a mixture of 5ml of 0.25-0.5% bupivacaine and 5ml absolute alcohol was injected.~For cases in which celiac ganglia could not be visualized, EUS-guided coeliac plexus neurolysis (CPN) will be performed.